follow up after colorectal cancer surgery
DESCRIPTION
TRANSCRIPT
![Page 1: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/1.jpg)
FOLLOW UP AFTER COLORECTAL CANCER
SURGERY
Andrew Luck
Colorectal SurgeonNorthern Adelaide Colorectal Unit
Adelaide, South Australia
Honorary Secretary, Colorectal Surgical Society of Australia and New ZealandCSSANZ representative, National Bowel Cancer Screening Program Advisory Group
CANCER SOCIETY OF NEW ZEALAND CANCER WEEK June 2009
![Page 2: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/2.jpg)
RATIONALE
• CRC patients at higher risk of a second primary (metachronous) tumour– Beck et al (1995)
• At 4 years• 7.7% new primary cancer• 62% new adenomatous polyp
• Early detection of recurrence– ?still curable
• Eg single liver or lung metastasis
![Page 3: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/3.jpg)
THE ARGUEMENTS
• Intensive versus routine follow-up
• If intensive, what tests and when?
![Page 4: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/4.jpg)
OVERVIEW
• Literature review– Intensive vs routine follow-up
• Assessment of individual procedures– Colonoscopy– Faecal occult blood tests (FOBT)– Carcinoembryonic antigen (CEA)– CT chest/abdomen/pelvis– Positron Emission Tomography (PET)
• Current Practice
![Page 5: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/5.jpg)
LITERATURE
• Randomised controlled trials comparing intensive vs minimal follow up– None showed a difference – ? Insufficient statistical power
• Meta-analyses– Ann Surg 1994 – non-randomised data– DCR 1998 – randomised and cohort studies– Renegan et al BMJ 2002 - ‘Impact on survival of
intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials’
![Page 6: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/6.jpg)
METHODS
• Medline• Embase• CANCERLIT• Cochrane controlled trials register
• Handsearches– Reference lists– Reviews– Abstracts from meetings– National trial registers
![Page 7: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/7.jpg)
INCLUSION CRITERIA
1. Study design (RCT)
2. Target population– patients with colorectal cancer treated
surgically with curative intent
3. Timing of randomisation– at or shortly after surgery
4. Availability of cancer specific survival data
![Page 8: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/8.jpg)
OUTCOME MEASURES• Primary
– All cause mortality at 5 years
• Secondary– Total number of recurrences– Any type of local recurrences– Isolated local recurrences– Any hepatic metastases– Isolated hepatic metastases– Lung metastases– Intraluminal recurrences– Metachronous colorectal cancers
![Page 9: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/9.jpg)
SUITABLE RCT
• Makela et al - Arch Surg 1995
• Ohlsson et al - DCR 1995
• Schoemaker et al - Gastro 1998
• Pietra et al – DCR 1998
• Kjeldsen et al – Br J Surg 1997
![Page 10: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/10.jpg)
MAKELA ET AL
INTENSIVE
• 3/12 2 years, 6/12– Exam, FBC, FOBT,
CEA, CXR, rigid sig.
• Colonoscopy 12/12• USS liver 6/12• CT 12/12
CONTROL
• 3/12 2 years, 6/12– Exam, FBC, FOBT,
CEA, CXR, rigid sig.
• Ba enema 12/12
![Page 11: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/11.jpg)
OHLSSON ET AL
INTENSIVE
• 3/12 2 years, 6/12– Exam, rigid sig, LFT,
CEA, FOBT, CXR
• Colonoscopy – 3, 15, 30, 60/12
• CT – 3, 6, 12, 18, 24/12
CONTROL
• No systematic follow up
![Page 12: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/12.jpg)
SCHOEMAKER ET AL
INTENSIVE
• 3/12 2 years, 6/12– Exam, FBC, LFT,
FOBT, CEA
• CXR 12/12• Colonoscopy 12/12• CT liver 12/12
CONTROL
• 3/12 2 years, 6/12– Exam, FBC, LFT,
FOBT, CEA
![Page 13: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/13.jpg)
PIETRA ET AL
INTENSIVE
• 3/12 2 years, 6/12– Exam, US liver,
CEA
• Colonoscopy 12/12• CXR 12/12• CT scan 12/12
CONTROL
• 3/12 2 years, 6/12– Exam, US liver,
CEA
• Colonoscopy 12/12• CXR 12/12
![Page 14: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/14.jpg)
KJELDSEN ET AL
INTENSIVE
• 6/12 3 years, 12/12– Exam, FBC, ESR,
LFT, FOBT, CXR, colonoscopy
CONTROL
• 5 and 10 years– Exam, FBC, ESR,
LFT, FOBT, CXR, colonoscopy
![Page 15: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/15.jpg)
ALL CAUSE MORTALITYTrial Intensive Control RR (95%)
Makela et al 23/52 (44) 27/54 (50) 0.88 (0.59-1.33)
Ohlsson et al 15/53 (28) 22/54 (41) 0.69 (0.41-1.19)
Schoemaker 43/167 (26) 55/158 (35) 0.74 (0.53-1.03)
Pietra et al 28/104 (27) 43/103 (42) 0.64 (0.44-0.95)
Kjeldsen et al 88/290 (30) 100/307 (33) 0.93 (0.73-1.18)
POOLED DATA
197/666 (30)
247/676 (37)
0.81
(0.70-0.94)
![Page 16: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/16.jpg)
ALL CAUSE MORTALITY
• Absolute reduction in mortality– 9-13%
• Number needed to treat (the number of patients needed to
prevent one death)– 8-11 patients
![Page 17: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/17.jpg)
TIME TO RELAPSE (MONTHS)
Trial Intensive Control Diff means (95%)
Makela et al 10.0 15.0 -5.0 (-7.99 to –2.01)
Ohlsson et al 20.4 24.0 -3.6 (-6.45 to –0.75)
Pietra et al 10.3 20.2 -9.9 (-11.19 to –8.61)
Kjeldsen et al 17.7 26.5 -8.8 (-10.25 to –7.35)
POOLED DATA
-8.5
(-9.37 to –7.62
![Page 18: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/18.jpg)
NHMRC GUIDELINES2005
“Intensive follow up is recommended for patients who have had surgery
for potentially curable disease”
Level of evidence I
Strength of recommendation A
![Page 19: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/19.jpg)
NHMRC GUIDELINES2005
• “…..although optimal investigation and pathways are yet to be firmly established”
![Page 20: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/20.jpg)
SURVEILLANCE OPTIONS
• For intraluminal recurrence and metachronous colorectal disease– Colonoscopy– Faecal occult blood tests
• For locoregional and distant metastases(NB 85% of recurrences by 2 years, 98.5% by 5 years DCR
2008)– Carcinoembryonic antigen– Radiology
• CT chest/abdomen/pelvis• Ultrasound liver• Chest X-ray
– PET scan
![Page 21: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/21.jpg)
COLONOSCOPY
• At the time of diagnosis– 2-4% synchronous cancer rate– 40% synchronous adenoma rate
• If not possible (obstructing cancer)– 3 to 6 months post operatively
• Timing of subsequent colonoscopy contentious
• Then 3 yearly, unless pathology found
![Page 22: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/22.jpg)
COLONOSCOPY
• Timing of first post op colonoscopy– NHMRC Guidelines
• 3 years
• But, – Early metachronous lesions (Beck et al)– Quality of initial colonoscopy
• Not performed by same specialist• Medicolegal consequences
• ‘Baseline’ colonoscopy at 12 months• Then 3 yearly unless pathology found
![Page 23: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/23.jpg)
![Page 24: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/24.jpg)
FAECAL OCCULT BLOD TESTS
• No evidence that FOBT adds to the effectiveness of a colonoscopy follow up program
![Page 25: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/25.jpg)
CARCINOEMBRYONIC ANTIGEN
• Antigen secreted by ~60% of colorectal cancers– Useful if raised at time of diagnosis– Less useful if not raised
• Serial CEA shown to decrease mortality from metastatic and recurrent disease (Renehan et al 2002)
• Perform 3-6 monthly
![Page 26: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/26.jpg)
RADIOLOGY
• CT liver shown to detect liver metastases and to define a group where hepatic resection is possible with the intent to cure
• USS liver not fully assessed• Chest Xray – insufficient data
• Why not CT chest/abdomen/pelvis?– Assessment of liver, lung and locoregional recurrence
in one investigation– Radiological investigation of choice
![Page 27: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/27.jpg)
PET SCAN
• Nuclear medicine test– Follow up of raised CEA where CT equivocal– PET/CT now available
• 2-[18F]fluoro-2-deoxy-D-glucose(F-18-FDG)
– Radiolabelled analogue of glucose– Preferentially transported into malignant cells– Trapped in CRC cancer cells– Detected by gamma camera
![Page 28: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/28.jpg)
PET SCAN
• Flanagan (1998)– PET in patients with CEA rise– PET abnormal in 17/22– Biopsy or follow-up confirmed
recurrence– 4 patients had curative resections– PPV 89% NPV 100%
![Page 29: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/29.jpg)
PET SCAN
• Oguinbiyi (1997)– LOCAL Sensitivity PET 91% vs CT 52%
Specificity PET 100% vs CT 80%– LIVER Sensitivity PET 95% vs CT 74%
Specificity PET 100% vs CT 85%
• Schiepers (1995)– LOCAL Sensitivity PET 93% vs CT 60%– Specificity PET 97% vs CT 72%– LIVER Sensitivity PET 94% vs CT 85%
![Page 30: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/30.jpg)
CURRENT PRACTICE
• Clinical review – 3/12 for 2 years– Yearly until 5 years– Encourage review if symptoms occur
• Colonoscopy– At diagnosis
• At 3-6 months if incomplete preop– At 12 months– Every 3 years
![Page 31: Follow Up After Colorectal Cancer Surgery](https://reader033.vdocuments.site/reader033/viewer/2022061203/547d09a8b4af9fd95b8b45a0/html5/thumbnails/31.jpg)
CURRENT PRACTICE
• CEA– 3/12 for 2 years
• CT chest/abdomen/pelvis– At 12 and 24 months
• PET/CT– If CEA rises